Pharvaris is a preclinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.

Pharmaceutical

Pharvaris

Pharvaris' headquarters in Zug, Switzerland

The Leiden office focuses on clinical research, human resources, and operational management for pharmaceutical innovations.

Leiden

Berndt Modig

Brian Pfister

Atsuko Tanaka

Miranda van Loon

Huib de Weerd

Juan Bravo

Stefan Abele

Jochen Knolle

Chris Wilson

Mary Burke Uhlenhopp

Justin Bush

Christa Milley

David Nassif

Maggie Beller

Wim Souverijns

David Meeker

Robert Glassman

Hans Schikan

Elisabeth Björk

Viviane Monges

This department oversees the clinical development process, regulatory affairs, and medical strategies to ensure the effective management of clinical trials and product development.

Clinical Development and Affairs

The Clinical Operations and Management team at Pharvaris is responsible for overseeing the planning, execution, and management of clinical trials to evaluate the safety and efficacy of the company’s novel oral bradykinin B2 receptor antagonist. This team ensures compliance with regulatory requirements, manages clinical documentation and inspection readiness, coordinates clinical supply logistics, and leads cross-functional collaboration to optimize trial operations. By leveraging their expertise, they aim to facilitate the successful advancement of innovative therapies for hereditary angioedema and beyond.

Clinical Operations and Management

The Research and Development team at Pharvaris is responsible for advancing the discovery and development of novel oral bradykinin B2 receptor antagonists for hereditary angioedema. This multidisciplinary team leverages expertise in toxicology, pharmacology, and biostatistics to evaluate the safety and efficacy of new compounds through preclinical and clinical stages, ensuring compliance with regulatory standards while guiding innovative research initiatives. Their work is pivotal in transforming promising small molecules into viable therapeutic options for patients.

Research and Development

The Leadership Team at Pharvaris is responsible for guiding the company’s strategic direction and overseeing the development of innovative therapeutic solutions for hereditary angioedema and other indications. This team comprises experienced executives who collaborate on critical decisions related to research, development, business strategy, and regulatory pathways to ensure successful transition from preclinical stages to clinical trials and ultimately to market. Their combined expertise aims to leverage Pharvaris's proprietary compounds to provide effective oral alternatives to existing therapies.

Leadership Team

This department oversees the efficient functioning of operational processes and human resources within the organization.

Operations Management

This department ensures compliance with quality standards and oversees the management of quality systems.

Pharvaris

Org chart

Board & advisors

Teams

Clinical Development and Affairs

Clinical Operations and Management

Research and Development

Leadership Team

Operations Management

Quality Assurance

Offices

Pharvaris

Org chart

Board & advisors

Teams

Clinical Development and Affairs

Clinical Operations and Management

Research and Development

Leadership Team

Operations Management

Quality Assurance

Offices

Related companies